Processa Pharmaceuticals, Inc. PCSA 深 滬
已收盤 02-06 16:00:00 美东时间
2.38
+0.210
+9.68%
華盛通- 最 高2.45
- 今 開2.14
- 成交量 5.84万股
- 最 低 2.10
- 昨 收 2.17
- 總市值 539.25万
- 52周最高 19.635
- 市盈率 靜 --
- 換手率 2.58%
- 52周最低 2.05
- 委 比 45.62%
- 總股本 226.58万
- 歷史最高 7120.00
- 量 比 0.65
- 振 幅 16.13%
- 歷史最低 2.05
- 每 手 1
- 風險率 3.01%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Processa Completes Enrollment And Dosing Of 20 Patients For Planned Formal Interim Analysis In Ongoing Phase 2 Clinical Study Evaluating NGC-Cap In Patients With Breast Cancer; Interim Data To Be Reported In Q1
Interim safety and efficacy data to be reported in Q1VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage biopharmaceutical company developing Next Generation
01-05 22:18
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
Processa Pharmaceuticals completed enrollment and dosing of 20 patients for the interim analysis of its Phase 2 study evaluating NGC-Cap, a combination of PCS6422 and capecitabine, in advanced or metastatic breast cancer. The interim analysis, expected in Q1 2026, aims to compare safety and efficacy between NGC-Cap and capecitabine alone, and may guide potential dose adjustments or sample size changes. NGC-Cap is designed to enhance cancer-killin...
01-05 14:15
Processa Pharma Provides Clinical Update On Ongoing Phase 2 Study Of NGC-Cap, Combination Treatment Of PCS6422 And Capecitabine, In Patients With Advanced Or Metastatic Breast Cancer
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabineCompany on track to conduct formal interim analysis in
2025-12-17 21:06
Processa Pharmaceuticals To Effect 1-For-25 Reverse Stock Split
On December 12, 2025, Processa Pharmaceuticals, Inc. (the "Company") filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the "Certificate of Amendment") to the Company's Fourth Amended
2025-12-16 00:07
Processa Pharma's Abstract, "Adaptive Phase 2/3 Study For PCS499 (499) In Patients With Focal Segmental Glomerulosclerosis (FSGS)", Accepted For Presentation At ASN Kidney Week 2025
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments for rare diseases, today announced that its
2025-11-05 22:16
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Replimune Group (NASDAQ:REPL) stock increased by 95.3% to $8.79 during...
2025-10-20 20:08
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares rose 113.4% to $3.99 during T...
2025-10-09 20:07
Processa Pharmaceuticals shares are trading higher. The stock has recently gained social media buzz.
Processa Pharmaceuticals shares are trading higher. The stock has recently gain...
2025-10-09 00:56
Why Processa Pharmaceuticals Stock Rose Almost 38% Overnight?
Processa Pharmaceuticals shares jumped 37.5% after hours following a strong regular session, despite facing significant losses over the past year.
2025-10-08 15:40
Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket
Shares of Telomir Pharmaceuticals Inc (NASDAQ:TELO) rose sharply in pre-market ...
2025-10-07 17:28
